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ABSTRACT
Osteonecrosis of the jaw (ONJ), a side-effect of bisphos-
phonate therapy, is characterized by exposed bone that 
fails to heal within eight weeks. Healing time of oral 
epithelial wounds is decreased in the presence of amino-
bisphosphonates; however, the mechanism remains 
unknown. We examined human tissue from individuals 
with ONJ and non-bisphosphonate-treated control 
individuals to identify changes in oral epithelium and 
connective tissue. Oral and intravenous bisphosphonate-
treated ONJ sites had reduced numbers of basal epithe-
lial progenitor cells, as demonstrated by a 13.8 ± 1.1% 
and 31.9 ± 5.8% reduction of p63 expression, respec-
tively. No significant differences in proliferation rates, 
vessel density, or macrophage number were noted. In vitro 
treatment of clonal and primary oral keratinocytes with 
zoledronic acid (ZA) inhibited p63, and expression was 
rescued by the addition of mevalonate pathway interme-
diates. In addition, both ZA treatment and p63 shRNA 
knock-down impaired formation of 3D Ex Vivo Produced 
Oral Mucosa Equivalents (EVPOME) and closure of an 
in vitro scratch assay. Analysis of our data suggests that 
bisphosphonate treatment may delay oral epithelial heal-
ing by interfering with p63-positive progenitor cells in 
the basal layer of the oral epithelium in a mevalonate-
pathway-dependent manner. This delay in healing may 
increase the likelihood of osteonecrosis developing in 
already-compromised bone.
KEY WORDS: osteonecrosis, oral pathology, gingi-
val, epithelia, keratinocytes, zoledronic acid.
InTRODuCTIOn
Osteonecrosis of the jaw (ONJ) is a side-effect of bisphosphonate (BP) therapy characterized by dehiscence of oral epithelium and exposure of 
bone that fails to heal within 8 wks in individuals without history of radiation 
therapy (Novince et al., 2009). The majority of cases occur in those who are 
taking therapeutic doses of high-potency intravenous (IV) bisphosphonates 
such as zoledronic acid (ZA) and pamidronate disodium (Woo et al., 2006). 
Amino-bisphosphonates suppress bone turnover by inhibiting osteoclast for-
mation and promoting apoptosis. This occurs through inhibition of farnesyl 
and geranyl–geranyl moiety production, resulting in reduced isoprenylation of 
the GTPases required for maintenance of cytoskeletal structure and vesicular 
traffic (Luckman et al., 1998; Fisher et al., 1999; Bergström et al., 2000). 
There are many hypotheses regarding the development of ONJ, but the exact 
mechanism has not been determined (Novince et al., 2009). Retrospective 
studies have associated trauma to the dento-alveolar complex with risk of 
developing ONJ. However, this does not explain why trauma to the alveolar 
soft tissue, spontaneously or during periodontal surgery, is the initiating event 
in a significant percentage of individuals, over 25% of cases in some series 
(Marx et al., 2005). This suggests the possibility of a direct role of compro-
mised oral mucosal wound healing in the pathogenesis of ONJ.
Following loss of continuity of epithelial coverage, inflammatory cells 
migrate to the wound site (Warburton et al., 2005). Secreted factors then 
stimulate proliferation and migration of connective tissue fibroblasts, which 
coordinate with neo-vascularization and re-epithelialization to result in 
wound regeneration (Stephens and Genever, 2007). Alterations in any of these 
pathways would lead to delayed soft-tissue healing at sites of injury, prolong-
ing the time during which the underlying bone is exposed to pathogenic oral 
flora and increasing the likelihood of osteonecrosis developing in already-
compromised bone.
To determine whether bisphosphonate-related inhibition of re-epitheliali-
zation plays a role in the pathogenesis of ONJ, we examined archival human 
tissue harvested from individuals with ONJ and from non-bisphosphonate-
treated control individuals to identify changes in the oral epithelium and con-
nective tissue. Since re-epithelialization involves reciprocal interactions 
between epithelial cells at the border of an ulcer, the underlying connective 
tissue, surrounding inflammatory mediators, and neo-vascularization, aspects 
of each of these processes were measured. P63, a selective marker of basal/
stem cells of stratified epithelium (Pellegrini et al., 2001), is constitutively 
expressed in basal cell nuclei of squamous epithelium. P63 has multiple 
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diverse isoforms (Little and Jochemsen, 2002) and is required 
for initiation of epithelial stratification during the development 
and maintenance of basal keratinocytes in mature epidermis 
(Mills et al., 1999; Yang et al., 1999; Koster et al., 2004; Senoo 
et al., 2007). We hypothesized that alterations in the numbers of 
p63-positive progenitors may link ONJ to delayed epithelial 
wound healing, as observed with bisphosphonate treatment 
(Amagase et al., 2007; Kobayashi et al., 2010).
MATERIAlS & METHODS
Immunohistochemistry
Formalin-fixed sections were deparaffinized in xylene and rehy-
drated. Heat-induced antigen retrieval (p63, Ki67, CD68) was per-
formed in citrate buffer (Citrate pH6.0TM, Dako:S1699, Carpinteria, 
CA, USA). FactorVIII-stained specimens were pre-treated with 
protease K. Antigen retrieval was not performed for PCNA.
Slides were stained with a Dako AutoStainerTM (Carpinteria, 
CA, USA) with either the labeled streptavidin-biotin method 
(p63 and Ki67; DakoCytomation LSAB+ System-HRPTM, 
Dako:K0690) or peroxidase-labeled polymer conjugated to sec-
ondary antibody (DakoCytomation EnVision+ System-HRP 
Labeled PolymerTM) anti-mouse (PCNA, CD68; Dako:K4001) 
or anti-rabbit (von Willebrand factor; Dako:K4003), developed 
with DAB (Liquid DAB+ Substrate SystemTM, Dako:K3468) 
and counterstained with hematoxylin. Endogenous peroxidase 
activity was blocked by five-minute immersion in 3% hydrogen 
peroxide (Peroxidase Block SolutionTM, Dako:S200130-2). 
Primary antibodies and dilutions were: p63 (1:100, Neomarker/
LabVision:MS-1081-P1); Ki67 (1:50, Dako:M7240); PCNA 
(1:100, Dako:M0879); CD68 (1:1600, Dako:M0814); and 
FactorVIII (1:250, Dako:A0082).
Two blinded researchers examined all slides independently. 
For p63, Ki67, and PCNA, the percentage of positive-staining 
nuclei in the basal layer and the 2 layers of epithelial cells 
immediately superior (suprabasal) were determined in a single 
representative field (Bortoluzzi et al., 2004). For FactorVIII,
the numbers of small, medium, and large vessels in a representa-
tive field were counted. For CD68, the number of positive cells 
in a representative field was counted. Results are reported as the 
average of the two examiners’ values.
nOK-SI Culture
Spontaneously immortalized oral keratinocyte line ‘NOK-SI’ (a 
generous gift of Rogerio Castilho, University of Michigan) cul-
ture and scratch assay were performed as described previously 
(Castilho et al., 2010). Cells were maintained in DMEM, 10% 
FBS, and penicillin/streptomycin. Scratches were generated with 
a 200-μL pipette tip and “healed” in 5% serum after treatment 
with ZA (Zometa®, Novartis, Basel, Switzerland). For immuno-
histochemistry, cells were cultured in Permanox® chamber-slides 
(Lab-Tek:700400, Rochester, NY, USA), fixed in methanol, per-
meabilized in 1% Triton-X-100, blocked in 2.5% goat serum/2.5% 
donkey serum/0.1% Triton-X-100, and dual-stained with 1:400 
p63 and 1:200 β-tubulin (AbCam:6046, Cambridge, MA, USA). 
Secondary antibodies were: 1:400 CyTM2 goat anti-rabbit and 
1:500 CyTM3 donkey anti-mouse (Jackson ImmunoResearch, West 
Grove, PA, USA). We determined positive p63 staining by gener-
ating an image composite of 3 random fields per sample, convert-
ing to 8-bit image, and then applying a common threshold with 
ImageJ (Scion Corp., Frederick, MD, USA). The number of p63-
positive cells was normalized to the total number of cells per field.
Western Blot
Cells were treated with 5-15 μM trans,trans-Farnesol (FOH) 
(Sigma:277541, Sigma, St. Louis, MO, USA) or geranylgera-
niol (GGOH) (Sigma:G3278) where indicated. Western blot was 
performed as described previously with minor modification 
(Scheller et al., 2010). Nuclear extracts were harvested with the 
Active Motif kit (Cat:40010). Cells were collected in ice-cold 
PBS and centrifuged, followed by re-suspension in 1x hypotonic 
buffer, 15 min. Detergent was added for cytoplasmic lysis, and 
nuclei collected by centrifugation. Nuclear pellet underwent 
lysis in RIPA buffer (Santa Cruz:24948, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) as described previously 
(Scheller et al., 2010). Whole-cell extracts were made when 
complete cell pellets underwent lysis with RIPA buffer. A 6- to 
8-μg (nuclear extract) or 20- to 25-μg (whole-cell extract) quan-
tity per lane was probed with 1:500 anti-p63, 1:1000 TATA 
binding protein (AbCam:ab818), or 1:1000 GAPDH (Chemicon® 
International: MAB374, Billerica, MA, USA), followed by 
1:3000 goat-anti mouse (Santa Cruz: 2005).
shRnA
Lentiviral shRNA clones in a pGIPZ vector from Open 
Biosystems (Thermo Scientific, Huntsville, AL, USA) were 
screened for ability to knock down p63. Virus was produced by 
the University of Michigan Vector Core with University of 
Michigan IBC approval. Clone V2LHS_24246 targeted against 
GenBank accession NM_003722 was selected. Cells were trans-
duced at ~3-6 MOI in complete media with 8 μg/mL polybrene 
(Santa Cruz:134220) overnight. Control cells were transduced 
with scrambled pGIPZ vector. 1oOK were assayed after 4 days, 
and NOK-SI were selected in 1 μg/mL puromycin (Santa 
Cruz:108071) for 3 passages before utilization.
Primary Keratinocytes and EVPOME
Human oral mucosal tissue harvesting was approved by the 
University of Michigan IRB (Appendix Table 2). Primary human 
oral keratinocyte (1oOK) culture and Ex Vivo Produced Oral 
Mucosa Equivalents (EVPOMEs) have been described previ-
ously (Izumi et al., 1999, 2003). Briefly, 1oOK were enzymati-
cally dissociated from tissue samples, and cells were cultured in 
chemically defined medium (EpiLife+EDGS; 0.06 mM calcium; 
25 μg/mL gentamicin; 0.375 μg/mL fungizone) (Invitrogen, 
Carlsbad, CA, USA). For EVPOMEs, 200 K cells/cm2 were 
seeded on 1 cm2 acellular cadaver skin (AlloDerm®) that was pre-
soaked in 5 μg/cm2 human type IV collagen at 4°C overnight. 
Cells+AlloDerm® were submerged in medium containing 1.2 mM 
calcium for 4 days before being raised to an air-liquid phase for 7 
days. A 10−5 M quantity of ZA was added on day 3. Samples were 
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fixed in 10% formalin with immunohistochemistry of 1oOK as 
above; immunohistochemistry for paraffin-sectioned EVPOMEs 
was as above with minor modification. Slides were processed 
manually, and p63 signal was amplified 
with ImmPRESS reagent (VectorLabs: 
MP-7500, Burlingame, CA, USA) and 
imaged with ImmPACT DAB substrate 
(VectorLabs:SK-4105).
Statistical Analysis
One-way ANOVA for 3 independent 
samples was performed with VassarStats 
(R. Lowry, Vassar College, Poughkeepsie, 
NY, USA). To compare individual 
groups, we used a two-tailed, homosce-
dastic t test. Differences were statisti-
cally significant when p < 0.05 and of 
non-significant trend when p < 0.100.
RESulTS
Human Tissue Analysis
The number of p63-positive cells in the 
basal and parabasal layers was higher in 
the control tissue (86.1 ± 3.4) as com-
pared with the Oral-BP (74.2 ± 6.1, p = 
0.087) and IV-BP (58.6 ± 10.6, p = 0.010) 
groups (Appendix, Figs. 1A, 1B). No dif-
ferences in epithelial or stromal prolifera-
tion rates were noted, as measured by 
Ki67 and PCNA (Fig. 1A). Likewise, no 
significant differences were noted in con-
centration of macrophages or blood ves-
sel density, as determined by CD68 and 
FactorVIII expression, respectively (Fig. 
1A). A non-significant trend toward 
increased numbers of CD68-positive 
macrophages was observed in the IV-BP 
group (Fig. 1A).
ZA Suppression of p63 Is 
Mevalonate-pathway-dependent
NOK-SI cells were treated for 24 hrs with 
increasing concentrations of ZA. 
Decreases in numbers of p63-positive 
cells were observed at 10−6 M (46.8 ± 
11.8%, p = 0.030) and 10−5 M ZA (25.2 ± 
14.4%, p = 0.014) when compared with 
controls (86.5 ± 2.66%) (Figs. 2A, 2B). 
The addition of mevalonate pathway 
intermediates restored p63 expression. 
FOH increased p63 in nuclear extracts 
(Fig. 2C) and immunohistochemically 
(Fig. 2D) in a dose-dependent manner, 
from 5-15 μM. Regulation of p63 expres-
sion by GGOH occurred at 5 μM in the 
nuclear extract but not during immunohistochemical analysis 
(Figs. 2C, 2D). A similar decrease in numbers of p63-positive 
cells after ZA treatment was observed with 1oOK after 10−6 M 
Figure 1. Bisphosphonates inhibit expression of p63 in basal oral keratinocytes. (A) Tabulated 
immunohistochemistry results. (B) Representative images of control, Oral-BP, and IV-BP 
epithelial staining for p63. Results are reported as average ± standard error of the mean.
Figure 2. Zoledronic acid inhibits p63 in clonal oral keratinocytes. (A) Immunocytochemistry 
depicting p63 nuclear stain (red) and B-tubulin cytoplasmic stain (green). (B) Percentage p63-
positive cells as calculated by applying a common threshold to matched p63-stained images 
and comparison with total number of cells per field. Results are reported as the average of 3 
independent experiments (N = 3), with 3 random fields analyzed per treatment regimen per 
experiment. (C) Representative Western blot of nuclear extracts from NOK-SI treated with 10-5 
M ZA, vehicle control, FOH, or GGOH. Band densitometry was used to normalize p63 to the 
TATA binding protein (TBP) loading standard. (D) Percentage p63-positive cells calculated as in 
(B) after treatment with vehicle (NT), 10-5 M ZA, ZA+5-15 μM FOH, or ZA+5-10 μM GGOH. 
(a) Significantly less than NT control; (b) significantly higher than the ZA group; (c) significantly 
higher than the 10 FOH group. Results are reported as mean ± standard deviation.
J Dent Res 90(7) 2011  Bisphosphonates Inhibit Expression of p63  897
(43.3 ± 1.6%, p = 0.008) and 10−5 M (46.1 
± 6.3%, p = 0.018) ZA treatment com-
pared with controls (74.4 ± 11%) (Fig. 
3A).
ZA and p63 Regulate Formation of 
Stratified Epithelium in 3D Culture
Lentiviral shRNA was used to knock 
down p63 expression in NOK-SI (Fig. 
3B) and 1oOK (Fig. 3C). After 4 days, 
1oOK were harvested and seeded on type 
IV collagen-coated AlloDerm® for 
EVPOME formation. Upon EVPOME 
analysis, significant qualitative differ-
ences were noted between the groups. 
Control 1oOK transduced with scram-
bled shRNA showed robust formation of 
keratinized, stratified squamous epithe-
lium, 3 to 8 cells thick, with generalized 
rete ridge formation (Fig. 3D). Treatment 
with ZA reduced the thickness to 1 to 3 
cells with few or no rete ridges (Fig. 
3D). Knock-out of p63 nearly ablated 
the ability of the cells to form an epithe-
lial layer, with > 90% of the surface 
lacking any epithelial attachment. In 
places where cells persisted, the acan-
tholytic epithelium was 1 to 2 cells thick 
(Fig. 3D). Immunohistochemistry for 
p63 revealed robust expression in the 
control group basal/parabasal layer (79.8 
± 16.9%), with significant inhibition 
after ZA treatment (39.9 ± 10.6%, p = 
0.044) (Fig. 3E). No p63-positive cells were noted on the p63 
knock-out EVPOMEs.
ZA and p63 Regulate Scratch-healing and Proliferation
NOK-SI were plated at high density before being uniformly 
scratched, and ZA was added directly before scratch generation. 
After 20 hrs, both 10−6 M and 10−5 M ZA groups showed a sig-
nificant delay in healing that continued up to 36 hrs (Figs. 4A, 
4B). Similarly, NOK-SI with stable knock-down of p63 had 
significantly impaired scratch closure after 24 hrs (Fig. 4C). In 
addition, the cell morphology was altered, with more spreading 
and decreased density (Fig. 4D). Proliferation defects at all 
time-points from 30 hrs on appeared only in the 10−5 M ZA 
group (Appendix Fig. A). However, proliferation decreases 
were also noted with 10−6 M ZA at 30 hrs and 10−7 M ZA at 56 
hrs (Appendix Fig. A). Proliferation of p63 knock-out cells was 
also impaired, as shown by a significant 22% decrease in the 
slope of their exponential growth phase when compared with 
that of scrambled controls (Appendix Fig. B).
DISCuSSIOn
Inhibition of mucosal wound healing in vivo and in vitro has 
been demonstrated after bisphosphonate treatment (Amagase 
et al., 2007; Landesberg et al., 2008; Kobayashi et al., 2010), 
yet the mechanism and its role in the pathogenesis of ONJ 
remain unknown. We present evidence, both in vivo and in vitro, 
that bisphosphonates can decrease the number of p63-positive 
basal epithelial progenitor cells. We hypothesize that this con-
tributes to reduced epithelial healing and speculate that this may 
potentiate insults to the oral cavity, increasing the risk of ONJ 
development in already-compromised bone.
Since re-epithelialization involves reciprocal interactions 
among epithelial cells, underlying connective tissue, the sur-
rounding inflammatory mediators, and neo-vascularization, we 
examined aspects of several of these components. Amino-
bisphosphonates block bone resorption through inhibition of 
osteoclast formation and function. Although the macrophage 
originates from a common precursor, much less is known about 
the effects of bisphosphonates on macrophage activity. We found 
a non-significant trend (p = 0.069) for increased macrophage 
numbers in the IV bisphosphonate group. Amino-bisphosphonates 
have also been shown to be inhibitors of angiogenesis (Giraudo 
et al., 2004; Amagase et al., 2007). However, we failed to identify 
changes in blood vessel density between tissue samples from 
bisphosphonate-treated and control individuals.
Adverse effects of amino-bisphosphonates on mucosal tis-
sues in the clinical setting range from esophageal erosions and 
gastrointestinal disturbances to oral ulcerations following direct 
Figure 3. Zoledronic acid (ZA) inhibits p63 in primary oral keratinocytes (1oOK), and both ZA 
and p63 regulate Ex Vivo Produced Oral Mucosa Equivalents (EVPOME) formation. (A) 
Percentage p63-positive 1oOK calculated as in Fig. 2B. Red = p63, Green = β-tubulin, arrows 
= cell nuclei. (B,C) Western blot of p63 in whole-cell extract after shRNA knock-down in clonal 
NOK-SI keratinocytes or 1oOK, VC: scrambled shRNA virus control. (D) Representative images 
from 3D EVPOMEs formed after 200 K 1oOK/cm2 seeding onto type IV collagen-coated 
AlloDerm® (N = 3). (E) Representative images and quantification of p63 staining in the basal/
parabasal layers of EVPOMEs (N = 3). Results are reported as mean ± standard deviation.
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epithelial contact (Gonzalez-Moles and Bagan-Sebastian, 2000; 
Monkkonen et al., 2003; Rubegni and Fimiani, 2006). The 
adverse effects on the gastric mucosa appear to be related to the 
mevalonate pathway, resulting in inhibition of proliferation and 
increased apoptosis of gastric epithelial cell lines at concentra-
tions of bisphosphonates around 10−5 M (Suri et al., 2001). In our 
study, both treatment with ZA and knock-down of p63 in 
NOK-SI cells showed reduction in proliferation. However, this 
proliferation defect was not observed in human ONJ biopsies 
with PCNA or Ki67 staining. This is likely because our biopsy 
sample size was not large enough for a significant difference to 
be detected.
Previous literature, our in vitro scratch assay, and 3D 
EVPOME formation support the notion that p63 expression is 
necessary for formation of a mature stratified squamous epithe-
lium (Yang et al., 1999). Treatment of both NOK-SI clonal and 
1oOK with 10−5 M ZA mimicked the delayed scratch healing, 
decrease in proliferation, and poor 3D EVPOME formation 
observed upon knock-down of p63. This strongly suggests that 
inhibition of p63 expression by amino-bisphosphonates, as was 
observed in ONJ biopsy specimens, in vitro cell cultures, and 
3D EVPOMEs, may contribute to decreased stratification and 
delayed wound healing. Partial percent p63 inhibition by ZA, as 
opposed to near-complete inhibition with shRNA, is likely 
responsible for the decreased severity of the ZA-treated pheno-
type when compared with p63 shRNA in our scratch and 
EVPOME assays. This may also be one reason bisphosphonates 
delay but do not completely inhibit epithelial healing in vivo.
Last, analysis of our data implies that bisphosphonate regula-
tion of p63 likely occurs via the inhibition of farnesylation and 
modulation of the mevalonate pathway. Inhibition of p63 expres-
sion by oral keratinocytes was rescued dose-dependently by the 
addition of FOH and, less consistently, by GGOH. There are 
relatively few known farnesylated proteins; one study identified 
17, including several members of the Ras protein family (Kho 
et al., 2004). Though we do not yet understand how farnesylated 
proteins regulate p63 expression, a recent publication found that 
overexpression of H-Ras in immortalized keratinocytes 
increased vimentin and p63 co-localization in vitro (Vaughan
et al., 2009). This suggests that inhibition of H-Ras farnesyl-
ation by ZA may have an opposing effect and reduce nuclear 
p63 accumulation, as observed in this study. Future work will be 
Figure 4. Zoledronic acid and p63 delay scratch closure in vitro. (A,B) Confluent layers of NOK-SI cells were treated with increasing concentrations 
of ZA and uniformly scratched with a 200-μL pipette tip. Closure was measured at 20 and 36 hrs. N = 6-8 unique scratches per group. (a) 10−6 
M ZA significance; (b) 10−5 M ZA significance. (C) Confluent NOK-SI maintained in 1 μg/mL puromycin with stable knock-down of p63 were 
uniformly scratched. Closure was measured at 24 and 40 hrs (N = 5-7). (D) Morphology of cells at 24 hrs showed decreased cell density in the 
shRNA p63 group. Results are reported as mean ± standard deviation.
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necessary to explore isoprenylated intermediates and their abil-
ity to regulate p63 expression in keratinocytes.
In summary, our results suggest that bisphosphonates may 
delay mucosal wound-healing and potentially predispose to the 
development of ONJ by reducing the number of p63-positive 
epithelial progenitor cells in a mevalonate-pathway-dependent 
manner. Our complementary studies have indicated that similar 
effects on p63 expression, wound closure, and epithelial stratifi-
cation are observed when human oral keratinocytes are treated 
with 10−6 M to 10−5 M ZA in vitro, suggesting that this may be 
a relevant test concentration for future studies. Future work will 
include exploration of regulation of p63 by isoprenylated inter-
mediates, as well as expansion of our analysis to determine if an 
individual’s susceptibility plays a role in bisphosphonate regula-
tion of epithelial p63 expression.
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